Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
27 nov. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Elecsys® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory...
Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List
16 nov. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
It is estimated that one third of the global population could be at risk for infection with Hepatitis E virus.1The new tests allow clinicians to diagnose acute and chronic infections amongst patients...
Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
14 nov. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all...
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation
09 nov. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Roche Elecsys NfL aids in detection of disease activity in adults with Multiple Sclerosis supporting better disease management decisionsElecsys NfL offers a minimally invasive testing option that can...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
30 oct. 2023 16h01 HE
|
F. Hoffmann-La Roche Ltd
Elevidys-treated boys aged 4-7 years with Duchenne showed an increase on the North Star Ambulatory Assessment (NSAA), a measure of motor function, compared to placebo at 52 weeks but the primary...
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
27 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early...
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
23 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum trotz Rückgang der Nachfrage nach COVID-19-Produkten
19 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 19. Oktober 2023 Konzernverkäufe steigen in den ersten neun Monaten um 1%1 zu konstanten Wechselkursen (CER), mit einem deutlichen Wachstum von 7% im dritten Quartal Konzernverkäufe ohne...
[Annonce événementielle au sens de l’art. 53 RC] Roche fait état d’une bonne croissance de ses ventes malgré une baisse de la demande de produits liés au COVID-19
19 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Bâle, le 19 octobre 2023 Les ventes du groupe ont augmenté de 1 %1 à taux de change constants (TCC) au cours des neuf premiers mois, avec une forte augmentation de 7 % au troisième trimestreSans les...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
19 oct. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 19 October 2023 Group sales grow by 1%1 at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products, Group sales...